3.75mg Mounjaro: the in-between dose explained

The decision most people are really facing when they search for 3.75mg Mounjaro

Usually, someone searching for 3.75mg is caught between two licensed doses (typically 2.5mg and 5mg) and is wondering whether a halfway point exists. That instinct is understandable. If 2.5mg felt manageable but the jump to 5mg brought more nausea than you wanted, a middle ground sounds sensible. The difficulty is that Mounjaro's KwikPen is factory-set to deliver a fixed volume at a fixed concentration. Each pen is pre-filled for a complete four-week course at one strength. There is no dial, no adjustment, and no way to draw a partial dose without departing entirely from how the medicine was tested and approved.

The licensed titration schedule, as described in the NHS patient information page for tirzepatide, moves in defined steps: 2.5mg for four weeks, then 5mg, and so on upward in 2.5mg increments. Each rung exists because that interval is where the clinical evidence sits. Skipping steps or engineering intermediate doses means your prescriber is working without the safety data that underpins each transition. That is the core of why splitting a pen is problematic, not a regulatory technicality.

If side effects at 5mg are the real concern, the right conversation is with your prescriber, staying on 2.5mg a little longer, or slowing the titration pace, is a clinically supported approach. Our frequently asked questions cover some of the practical questions around this. The decision belongs in that clinical relationship, not in a dose calculation at the kitchen table.

What actually happens at 2.5mg, and why that dose exists

The 2.5mg starter dose was designed to let your body adjust to tirzepatide before any meaningful therapeutic effect takes hold. It slows gastric emptying and activates GIP and GLP-1 receptors at a low level, enough to test your tolerance without the stronger appetite and GI effects that come later. For most people, side effects at 2.5mg are mild. The SURMOUNT-1 trial, published in the New England Journal of Medicine, showed average weight reductions of around 20–21% at the 15mg maintenance dose over 72 weeks, but that journey begins at 2.5mg and builds incrementally.

The consequence of this design is that if 2.5mg feels too easy or too slow, the answer is not to nudge toward 3.75mg. The dose is calibrated for adjustment, not for results. Some people notice very little at 2.5mg and feel impatient; that is expected. Others find even 5mg a stretch and need more time at each step. Both of those are normal presentations, and both are things a prescriber can plan around. You can read more about the full treatment picture on the Mounjaro overview page.

The 5mg pen, which follows 2.5mg in the licensed schedule, is covered in more detail for anyone wanting to understand what that transition typically involves. The point here is that the 2.5mg dose is doing a specific job, one that an improvised 3.75mg dose cannot reliably replicate.

The risks of using Mounjaro outside the licensed dosing framework

Splitting a pre-filled pen introduces practical problems beyond the licensing question. The KwikPen mechanism is not designed for partial delivery; attempting it risks inaccurate dosing, contamination of the remaining dose, and incorrect storage of an open pen. The Mounjaro SmPC, available on the Electronic Medicines Compendium, sets out storage conditions and administration steps that assume the pen is used as supplied. An improvised approach falls outside those conditions.

There is also a clinical oversight dimension. When a prescriber signs off a dose increase, they are making a judgement about your specific circumstances, weight, response, side-effect profile, any relevant health history. A self-administered intermediate dose bypasses that review entirely. If something goes wrong, neither the prescriber nor the pharmacy has visibility of what was actually taken. For people over 75 or with complex health backgrounds, that gap in oversight carries real weight; the considerations for older adults on Mounjaro are worth reading alongside this.

If cost is part of the reasoning behind splitting pens (making one pen stretch across eight weeks instead of four) it is worth reading an honest breakdown of what drives Mounjaro pricing in the UK before going down that path. The short version: the savings rarely justify the risks, and the clinical oversight you lose is the part you actually paid for.

What a prescriber can do instead, and how the process works at nume

The licensed schedule gives prescribers room to move. If you are finding the jump to 5mg difficult, a prescriber can keep you on 2.5mg for longer before titrating. That is fully within the guidance, and it is a conversation worth having. Missed doses, unexpected side effects, or a change in your circumstances can all affect the plan, our team covers what to do if you miss a Mounjaro dose as a separate resource, because that comes up regularly.

At nume, every dose change is reviewed by a GPhC-registered Independent Prescriber before a new pen is dispensed, a real clinician reading your notes, not an automated system making the call. If you are already on treatment elsewhere and thinking about moving to a more clinically supervised service, the transfer process is straightforward. Once your consultation is approved and dispatched by noon, DPD delivers to your door the next working day, tracked, in plain packaging, nothing on the outside to indicate what is inside.

If you are not yet on treatment and wondering whether Mounjaro is right for you, the free consultation is the place to start. A prescriber reviews your answers the same day, and you will have a clear answer on eligibility without any obligation to proceed. Tirzepatide's broader clinical profile (how it works, who it suits, and how it compares) is covered on the tirzepatide information page if you want that background first.